Sejong Medical세종메디칼

Sejong Medical's reported profits have recovered, but an October 2026 filing about missed bond payments is a serious concern.

On trailing twelve-month figures to H1 2026, the company reported revenue of ₩19.1B, operating income of ₩4.4B and net income of ₩2.5B, after heavy losses in 2022 to 2024. At ₩412 the market value is about ₩31.2B, and borrowings of ₩5.2B exceed cash of ₩10.2B, with liabilities at 129.7% of equity. The data does not explain the bond default or the company's response.

What stands out

• Net income swung from losses of ₩97B in 2022 and ₩64B in 2024 to ₩0.55B in 2025 and ₩2.5B on a trailing basis.
• Trailing operating margin is 23.2%, up from 14.2% in 2025, according to the filed statements.
• Trailing free cash flow is negative at about -₩146M, so profits are not yet turning into positive free cash flow.
• Recent filings include an October 2026 notice of failure to pay bond principal and interest, collateral provided for third parties in July and August, and a CEO change in June 2026.
• Valuation shows a P/E of 12.3 and a P/B of 1.2, with no dividend. Foreign ownership stayed at 1.7% over the last 60 days. No news headlines were included in the data.

What to watch

• Any further filings on the bond payment failure, creditor actions, and the company's plan to address its debt, none of which are in the data.
• The amended half-year report and the outcome of the shareholders' meeting, which were both recently amended or called.
• Whether profitability holds and free cash flow turns positive in upcoming results. Price returns and 52-week range figures are not available in the data.